Cargando…
A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging
BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer death and early stage diagnosis can greatly increase the survival rate of patient. However, the accurate detection of HCC remains an urgent challenge in medical diagnosis. The combination of magnetic resonance imaging (...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924661/ https://www.ncbi.nlm.nih.gov/pubmed/31908447 http://dx.doi.org/10.2147/IJN.S219794 |
_version_ | 1783481759276466176 |
---|---|
author | Sun, Jinghua Li, Xiaoyan Chen, Anqi Cai, Wenwen Peng, Xiaoyang Li, Liping Fan, Bo Wang, Lingjie Zhang, Huanhu Zhang, Ruiping |
author_facet | Sun, Jinghua Li, Xiaoyan Chen, Anqi Cai, Wenwen Peng, Xiaoyang Li, Liping Fan, Bo Wang, Lingjie Zhang, Huanhu Zhang, Ruiping |
author_sort | Sun, Jinghua |
collection | PubMed |
description | BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer death and early stage diagnosis can greatly increase the survival rate of patient. However, the accurate detection of HCC remains an urgent challenge in medical diagnosis. The combination of magnetic resonance imaging (MRI) and photoacoustic imaging (PAI) are conducive for accurate locating of cancerous tissue. Therefore, it is necessary to explore a more facile and biosafe dual-modal contrast agent for orthotopic HCC detection. METHODS: In this study, a promising contrast agent had been identified based on gadolinium chelated melanin nanoparticles and evaluated its usage as a dual-modal T(1) MRI and PAI contrast agent for orthotopic HCC detection. RESULTS: The gadolinium-based melanin nanoparticles presented ultrasmall size, high chelation stability and negligible cytotoxicity estimated by CCK-8 assay. Moreover, the nanoparticle exhibited higher r(1) relaxivity (45.762 mM(−1) s(−1)) than clinically approved Gadodiamide (4.975 mM(−1) s(−1)) at 1.5 T MR scanning. A linear regression analysis confirmed that the nanoparticles were ideal candidates for PAI in vitro. After the nanoparticles were injected into vein in mice with orthotopic HCC, a dramatic increase in signal of the liver was observed at 0.5 hr by MRI and PAI, while the tumor exerted remarkable signal enhancement at 7 hrs, showing excellent detection sensitivity. In addition, the nanoparticles exhibited excellent biocompatibility and they can be excreted through both hepatobiliary and renal pathways after diagnosis. CONCLUSION: These results indicate that the ultrasmall gadolinium chelated melanin nanoparticles is a promising candidate as a dual-modal MRI/PAI contrast agent for the detection of orthotopic HCC. |
format | Online Article Text |
id | pubmed-6924661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-69246612020-01-06 A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging Sun, Jinghua Li, Xiaoyan Chen, Anqi Cai, Wenwen Peng, Xiaoyang Li, Liping Fan, Bo Wang, Lingjie Zhang, Huanhu Zhang, Ruiping Int J Nanomedicine Original Research BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer death and early stage diagnosis can greatly increase the survival rate of patient. However, the accurate detection of HCC remains an urgent challenge in medical diagnosis. The combination of magnetic resonance imaging (MRI) and photoacoustic imaging (PAI) are conducive for accurate locating of cancerous tissue. Therefore, it is necessary to explore a more facile and biosafe dual-modal contrast agent for orthotopic HCC detection. METHODS: In this study, a promising contrast agent had been identified based on gadolinium chelated melanin nanoparticles and evaluated its usage as a dual-modal T(1) MRI and PAI contrast agent for orthotopic HCC detection. RESULTS: The gadolinium-based melanin nanoparticles presented ultrasmall size, high chelation stability and negligible cytotoxicity estimated by CCK-8 assay. Moreover, the nanoparticle exhibited higher r(1) relaxivity (45.762 mM(−1) s(−1)) than clinically approved Gadodiamide (4.975 mM(−1) s(−1)) at 1.5 T MR scanning. A linear regression analysis confirmed that the nanoparticles were ideal candidates for PAI in vitro. After the nanoparticles were injected into vein in mice with orthotopic HCC, a dramatic increase in signal of the liver was observed at 0.5 hr by MRI and PAI, while the tumor exerted remarkable signal enhancement at 7 hrs, showing excellent detection sensitivity. In addition, the nanoparticles exhibited excellent biocompatibility and they can be excreted through both hepatobiliary and renal pathways after diagnosis. CONCLUSION: These results indicate that the ultrasmall gadolinium chelated melanin nanoparticles is a promising candidate as a dual-modal MRI/PAI contrast agent for the detection of orthotopic HCC. Dove 2019-12-16 /pmc/articles/PMC6924661/ /pubmed/31908447 http://dx.doi.org/10.2147/IJN.S219794 Text en © 2019 Sun et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sun, Jinghua Li, Xiaoyan Chen, Anqi Cai, Wenwen Peng, Xiaoyang Li, Liping Fan, Bo Wang, Lingjie Zhang, Huanhu Zhang, Ruiping A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging |
title | A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging |
title_full | A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging |
title_fullStr | A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging |
title_full_unstemmed | A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging |
title_short | A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging |
title_sort | dual-modality mr/pa imaging contrast agent based on ultrasmall biopolymer nanoparticles for orthotopic hepatocellular carcinoma imaging |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924661/ https://www.ncbi.nlm.nih.gov/pubmed/31908447 http://dx.doi.org/10.2147/IJN.S219794 |
work_keys_str_mv | AT sunjinghua adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT lixiaoyan adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT chenanqi adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT caiwenwen adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT pengxiaoyang adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT liliping adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT fanbo adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT wanglingjie adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT zhanghuanhu adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT zhangruiping adualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT sunjinghua dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT lixiaoyan dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT chenanqi dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT caiwenwen dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT pengxiaoyang dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT liliping dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT fanbo dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT wanglingjie dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT zhanghuanhu dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging AT zhangruiping dualmodalitymrpaimagingcontrastagentbasedonultrasmallbiopolymernanoparticlesfororthotopichepatocellularcarcinomaimaging |